Wei-Ting Chang
Tainan, Taiwan
Location status: Recruiting
NCT Number: NCT05078814
Aldehyde dehydrogenase 2 (ALDH2) is an important enzyme protecting human from the accumulation of aldehyde, the main metabolites of alcohol. The deficiency of ALDH2 gene results in flush and hang over post drinking and most importantly it has been found associated with the incidence of cancer and post myocardial infarction (MI) heart failure. In the previous studies, ALDH2 decreased the ischemic territory post infarction and using a large scaled interaction of genetic variants and ALDH2 as an instrument, the threats of alcohol consumption on Asians' cardiovascular health was underscored. Furthermore, in a meta-analysis reviewing 12 case-control studies also indicated an increase of 48% risks in patients with ALDH2 deficiency. Notably, the genetic deficiency is most prevalent in Asians. In Taiwan one of every two individuals may be the victim and the high prevalence is counted as the top of the world. However, a large scaled prospective study focusing on the prevalence of ALDH2 deficiency in patients with peripheral artery occlusive disease (PAOD) or acute coronary syndrome (ACS)remains lacking.
Interested in participating?
Request Info20 year and older
All sexes
Observational
Tainan, Taiwan
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Observational research
Time frame: 2 years
Time frame: 2 years
Contact information is provided by the study sponsor or research team.
Chimei Medical Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06389149
Arterial Occlusive Diseases, Arteriosclerosis
Omaha, Nebraska, United States
View Trial DetailsNCT06951685
Peripheral Arterial Occlusive Disease 1, Peripheral Artery Occlusive Disease
San José, Costa Rica
View Trial DetailsNCT05737225
Percutaneous Transluminal Angioplasty, Peripheral Arterial Occlusive Disease 1
Ankara, Turkey (Türkiye)
View Trial DetailsNCT03023098
Peripheral Arterial Occlusive Disease 1, Peripheral Artery Occlusive Disease
Helsinki, Finland
View Trial Details